MAP3K7 and systemic sclerosis: It comes as no surprise that experimental small molecule inhibitors of TAK1, such as HS-276 [134,135], have shown promise by preventing TGF-β-stimulated collagen synthesis and myofibroblast differentiation in control skin fibroblasts as well as mitigating the profibrotic phenotype in SSc fibroblasts and bleomycin mouse models (see Asano et al. [136] for further discussion of TAK1 pharmacologic inhibition).